CGEM
Published on 05/07/2026 at 01:04 pm EDT
Cullinan Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 49.66 million compared to USD 48.5 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.74 a year ago.
Diluted loss per share from continuing operations was USD 0.75 compared to USD 0.74 a year ago.